Clinical trial
Randomized Trial of Fluticasone in Bronchial Premalignancy
NCT00407264 · Amsterdam UMC, location VUmc, Other · Completed
Key facts
| NCT number | NCT00407264 |
|---|---|
| Title | Randomized Trial of Fluticasone in Bronchial Premalignancy |
| Official title | The Influence of Fluticasone Inhalation on Intermediate Markers of Carcinogenesis in the Bronchial Epithelium of a High Risk Population : A Double Blind Placebo-Controlled Randomised Phase II Study |
| Lead sponsor | Amsterdam UMC, location VUmc, Other |
| Collaborators | GlaxoSmithKline Industry The Netherlands Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bronchogenic Carcinoma |
| Intervention type | Drug |
| Interventions | Fluticasone propionate |
| Enrollment | 90 |
| Start date | Feb 1, 2002 |
| Completion | Dec 1, 2005 |
| First posted | Dec 4, 2006 |
| Last update posted | Dec 4, 2006 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: